找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Hepatocellular Carcinoma:; Targeted Therapy and Kelly M. McMasters Book 2011 Springer Science+Business Media, LLC 2011 Bead Therapy.HCC.Int

[復(fù)制鏈接]
樓主: exposulate
31#
發(fā)表于 2025-3-26 21:20:34 | 只看該作者
Ultrasound-Guided Liver Resection for Hepatocellular Carcinoma,stoperative liver failure. In particular, the coexistence of liver cirrhosis in most cases of hepatocellular carcinoma (HCC) has a considerable adverse effect on the surgical results. As a matter of fact, recent series are still associated with mortality rates above 5%, which is not negligible [1].
32#
發(fā)表于 2025-3-27 01:28:19 | 只看該作者
33#
發(fā)表于 2025-3-27 05:36:45 | 只看該作者
34#
發(fā)表于 2025-3-27 13:16:27 | 只看該作者
35#
發(fā)表于 2025-3-27 17:36:42 | 只看該作者
36#
發(fā)表于 2025-3-27 18:22:13 | 只看該作者
Radiofrequency Ablation for Hepatocellular Carcinoma,worldwide due to its association with hepatitis B and C viral infections. Cirrhosis is present concurrently with HCC in approximately 90% of the identified cases [1, 2]. Furthermore, the incidence of HCC increases with the severity of cirrhosis. Follow-up studies have identified HCC as one of the mo
37#
發(fā)表于 2025-3-27 23:16:55 | 只看該作者
Transarterial Chemoembolization,CC). Its success is attributable to the ability to deliver high-dose chemotherapy into the tumor vascular bed. The addition of emulsifying agents (i.e., lipiodol) and/or particles to the chemotherapy slows down the blood flow through the tumor blood supply and increases the chemotherapy residence ti
38#
發(fā)表于 2025-3-28 05:45:01 | 只看該作者
Chemoembolization with Drug-Eluting Beads,ns a much larger fraction (20–40%) in developing countries and is the 5th–6th most common malignancy worldwide (approximately 5.6% of all cancers) [3, 4]. Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver (70–85%) with an estimated 500 thousand to 1 million new cases
39#
發(fā)表于 2025-3-28 09:30:06 | 只看該作者
40#
發(fā)表于 2025-3-28 10:49:56 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 05:31
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
栾川县| 柏乡县| 靖安县| 灯塔市| 张北县| 达日县| 慈利县| 海淀区| 都匀市| 四子王旗| 万州区| 罗平县| 大化| 芮城县| 浑源县| 西城区| 桑日县| 泾川县| 楚雄市| 隆化县| 南丹县| 丰镇市| 西丰县| 舞阳县| 正镶白旗| 呈贡县| 明水县| 灵台县| 宁阳县| 措勤县| 甘南县| 荥经县| 陈巴尔虎旗| 岳西县| 会泽县| 临夏市| 凤台县| 博爱县| 通渭县| 石棉县| 屏山县|